Clinical Research Directory

The Clinical Application Value of CAIX-Targeted PET Hypoxia Imaging in Malignant Tumors

This project involves conducting integrated PET/MR or PET/CT imaging using a CAIX-targeted PET tracer (e.g., \[68Ga\]Ga-DOTA-CAIX peptide) in clinically diagnosed malignant tumor patients, aiming to achieve the following objectives: Patients with malignant tumors: To visually assess the hypoxic state of malignant tumors, with pathological immunohistochemical detection of CAIX expression levels as the gold standard, evaluate the detection efficacy and quantitative accuracy of CAIX PET imaging for tumor hypoxic regions; clarify the location, extent, and heterogeneous distribution characteristics of hypoxic subregions within tumors; conduct a head-to-head comparison with \[18F\]FDG PET imaging to assess the complementary value and differences of the two imaging techniques in tumor boundary delineation, metastatic lesion detection, and tumor burden evaluation; based on the hypoxic biological information provided by CAIX PET imaging, assist clinicians in designing hypoxia-conformal margin expansion for radiotherapy target volumes, aiding in the determination of personalized radiotherapy and combined treatment plans.

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a monotherapy and potentially in combination therapy to patients with locally advanced or metastatic epithelial solid tumors.